诺和诺德质量总监在PDA/FDA圆桌会称错用无菌指南遭缺陷,低生物负载原料药放行标准不统一
诺和诺德质量总监:错用无菌相关指南遭缺陷,行业低生物负载原料药放行标准并不统一
在PDA/FDA联合监管大会前夕于2026年9月13日举行的“解读不同生产模式下的无菌生产监管要求”圆桌会议上,8位参会者反馈企业因套用并不适用于自身产品的无菌生产指南而被检查出具缺陷,多数参会者认为无菌药品环境洁净度要求是监管要求被错用的常见情形。
2026年9月13日,在PDA/FDA联合监管大会即将召开前夕,一场主题为 “解读不同生产模式下的无菌生产监管要求” 的行业圆桌会议汇聚制药行业生产负责人与专家,探讨生物制品生产中微生物负载控制的新兴监管要求。
This session—moderated by Andrew Chang, PhD, Senior Quality & Regulatory Director, Science, Policy and Intelligence at Novo Nordisk, with registration fees benefiting the Yali Christensen Early Career Professional Grant—brought together perspectives from consultants, manufacturers, and data scientists. Key topics included shifting regulatory expectations, applying EU GMP Annex 1: Manufacture of Sterile Medicinal Products principles, and balancing patient safety with operational costs.
本次会议由诺和诺德科学、政策与情报部门高级质量与监管总监 Andrew Chang 博士主持,会议注册费将用于资助 Yali Christensen 青年职业发展基金;参会人员涵盖咨询顾问、生产企业以及数据科学家。会议主要议题包括不断变化的监管要求、欧盟 GMP 附录 1《无菌药品生产》原则的应用,以及在患者安全与运营成本之间取得平衡。
Gathering Industry Feedback: The Slido Poll
收集行业反馈:Slido 线上投票
To kick off the discussion, a Slido poll surveyed participants about their experiences with regulatory inspections and compliance challenges:
为开启本次讨论,会议通过 Slido 线上投票调研参会者在监管检查及合规方面遇到的实际问题:
Eight attendees reported being cited for following sterile manufacturing guidelines that did not apply to their products.
8 位参会者反馈,企业因遵循并不适用于自身产品的无菌生产指导原则而被检查出具缺陷。
The majority pointed to sterile drug product environmental levels as a common source of misapplied regulatory expectations.
多数参会者指出,无菌药品的环境洁净度要求是监管要求被错用的常见情形。
Most participants indicated that their companies do not exclusively release batches with zero bioburden or zero endotoxin, highlighting the prevalence of “low bioburden”—but non‑sterile—drug substances and varied acceptance criteria across the industry.
大部分参会者表示,其企业并非只放行微生物负载、内毒素均为零的批次,这也反映行业内普遍存在 “低微生物负载但非无菌” 的原料药,且行业内各企业可接受标准各不相同。
Rethinking Annex 1: Richard Denk’s Perspective
重新审视附录 1:Richard Denk 的观点
Richard Denk, Senior Consultant at Skang AG, discussed applying Annex 1 (governing sterile products) to low‑burden biological intermediates and active pharmaceutical ingredients (APIs). He underscored the need for tailored contamination control strategies and pointed to PDA Technical Report 90: Contamination Control Strategy Development as an industry tool. Richard urged that facility and equipment design focus on true critical control points—not just compliance for its own sake—and warned that “raising the bar” without clear scientific justification could ultimately make medicines less accessible and affordable worldwide. Looking ahead, he noted a key PDA conference where African regulators would join to discuss achievable bioburden standards.
Skang AG 高级顾问 Richard Denk 探讨了将附录 1(无菌产品监管文件)应用于低微生物负载生物中间体以及原料药(API)。他强调需要制定定制化的污染控制策略,并指出 PDA 第 90 号技术报告《污染控制策略制定》可作为行业工具。Richard 主张厂房和设备设计应聚焦真正的关键控制点,而不是单纯为合规而合规;同时他警示,在缺乏明确科学依据的情况下 “提高标准”,最终可能会降低全球药品的可及性与可负担性。展望未来,他提及一场重要的 PDA 会议,非洲监管机构将参会共同探讨具备可实施性的微生物负载标准。
Bridging Science and Compliance: Novo Nordisk’s Challenges
打通科学依据与合规要求:诺和诺德遇到的现实挑战
Katherine Holm Juliussen of Novo Nordisk shared the journey from strict regulatory compliance toward a “science meets compliance” model. She described how regulators now expect manufacturers to provide scientific rationale and risk assessments for microbial limits, not just adherence to procedures. Common inspection observations include:
诺和诺德的 Katherine Holm Juliussen 分享企业从单纯严格遵守监管规定,转向 “科学支撑合规” 模式的实践历程。她介绍,如今监管机构要求生产企业针对微生物限度提供科学依据与风险评估,而不只是机械执行操作规程。检查中常见缺陷包括:
Inadequate assessment of microbial risks
微生物风险评估不充分
Undefined objectionable organisms
未明确界定有害微生物
Weak root cause analysis when trends appear
出现趋势性偏差时,根本原因分析工作不足
Katherine emphasized the need to demonstrate an end‑to‑end understanding of how bioburden is managed throughout the product lifecycle—while also lamenting the lack of well‑defined standards for “good enough” evidence to support a low bioburden strategy.
Katherine 强调,企业需要完整展示对产品全生命周期微生物负载管控的理解;同时她也提出,目前缺少清晰标准来界定支撑低微生物负载策略的证据需要达到何种充分程度。
Data‑Driven Insights: Redica’s Regulatory Analysis
基于数据的见解:Redica 公司监管数据分析
Michael de la Torre, CEO of Redica Systems, presented a data‑backed overview of 658 FDA observations from drug substance biologic sites (2020–2024). The key findings included:
Redica Systems 首席执行官 Michael de la Torre 基于 2020‑2024 年生物原料药生产场地的 658 条 FDA 检查缺陷,做数据化解读。主要结论如下:
Annex 1 principles are now showing up in FDA warning letters and observations for drug substance sites.
附录 1 的监管原则现已出现在针对原料药生产场地的 FDA 警告信及检查缺陷中。
Perceived regulatory “overreach” often reflects companies being cited for not following their own rigorous internal SOPs (for example, unnecessarily applying Grade A cleanroom protocols in lower‑grade environments).
很多被认为监管 “过度要求” 的情形,实际上是企业未执行自身制定的严格内部 SOP 而被出具缺陷(例如,在较低洁净级别环境不当套用 A 级洁净区要求)。
U.S. FDA expectations for bioburden control are moving further upstream in the manufacturing process—with an increasing trend toward requirements tighter than the traditional 10 CFU limits.
美国 FDA 对微生物负载控制的监管要求不断向生产工艺上游延伸,越来越多场景要求严于传统的 10 CFU 限度。
Conclusion
总结
A lively panel discussion delved into the implications of lowering bioburden limits. Andrew and Richard debated the scientific justification for moving from 10 CFU to 1 CFU prior to sterile filtration, questioning whether higher standards truly benefit patients given the cost and potential for supply chain disruption.
小组围绕降低微生物负载限度带来的影响展开热烈讨论。Andrew 与 Richard 就无菌过滤前将限度由 10 CFU 收紧至 1 CFU 的科学依据展开辩论,提出疑问:考虑到成本增加以及供应链中断风险,更高的限度标准是否真正对患者有益。
Finally, discussion turned to the core regulatory principle: for parenteral products (especially those that cannot be terminally sterilized), low bioburden and endotoxin control before filtration is expected, yet clear, globally harmonized standards remain elusive.
最后,会议聚焦核心监管原则:对于注射剂产品(尤其是无法进行终端灭菌的品种),过滤前需要做好微生物负载与内毒素控制;但全球尚未形成清晰统一的协调标准。
As regulatory standards evolve, ongoing dialogue—and open data sharing—will be crucial to navigating the future of pharmaceutical quality, and this roundtable had captured the complexity of evolving regulatory expectations and the industry’s commitment to data, science, and patient safety.
随着监管标准持续迭代,持续开展对话、公开共享数据,对于应对未来制药质量领域的挑战至关重要。本次圆桌会议充分展现监管要求不断演变带来的复杂性,也体现行业坚持以数据、科学为基础,保障患者安全的立场。
来源:制药经理人 · mp.weixin.qq.com